ASCO 2012 LC Highlights: Dr. Mark Socinski on Single Agent vs Doublet Chemo for PS2 (video)
Aug 19, 2012•7 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.
For the best experience, listen in Metacast app for iOS or Android